PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway
Shan Lin, Bangwei Wu, Shengjia Sun, Tao Sun
TL;DR
Alirocumab, a PCSK9 inhibitor, protects against diabetic heart disease by improving heart function and reducing damage through a specific signaling pathway.
Contribution
This study demonstrates that alirocumab improves diabetic cardiomyopathy via the ERK/p38 MAPK pathway, offering new therapeutic insights.
Findings
Alirocumab enhances cell viability and reduces oxidative stress in high-glucose H9c2 cells.
Alirocumab reduces myocardial hypertrophy and improves cardiac function in diabetic cardiomyopathy mice.
Alirocumab activates the ERK/p38 MAPK pathway to exert protective effects on diabetic hearts.
Abstract
PCSK9 is a gene associated with familial hypercholesterolemia and is involved in other biological processes such as apoptosis, autophagy, and inflammatory responses. This study aims to further validate whether PCSK9 inhibitors can improve diabetic cardiomyopathy and elucidate their mechanisms of action. This study utilized H9c2 cells and C57BL/6J mice to validate the efficacy of the PCSK9 inhibitor alirocumab through in vivo and in vitro experiments. In vitro, alirocumab was shown to enhance cell viability and reduce oxidative stress in H9c2 cells under high glucose stress. It can also decrease the expression levels of inflammatory reaction and mitochondrial apoptosis-related proteins. Through in vivo experiments, we demonstrated that alirocumab can reduce myocardial hypertrophy and improve cardiac function in diabetic cardiomyopathy mice. Meanwhile, alirocumab treatment increased…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLipoproteins and Cardiovascular Health · Cardiac Fibrosis and Remodeling · Cardiovascular Function and Risk Factors